Full-Time

Senior Scientist

Oncology Discovery Biology

Deadline 8/1/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$131.6k - $159.5k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Seattle, WA, USA

In Person

This position is site-essential, requiring 100% of shifts onsite at the Seattle facility.

Category
🧬Biology & Biotech (2)
,
Requirements
  • Bachelor’s Degree
  • 6+ years of relevant academic and / or industry experience
  • Master’s Degree
  • 4+ years of relevant academic and / or industry experience
  • Ph.D. or equivalent advanced degree in the Life Sciences
  • 2+ years of relevant academic and / or industry experience
Responsibilities
  • Identify and validate novel targets for development of T cell engagers.
  • Independently design, develop and execute novel *in vitro* and *ex vivo* cell-based assays/models to evaluate the efficacy and specificity of T cell engagers.
  • Apply knowledge of T cell biology to develop next-generation T cell engagers with improved efficacy and safety profiles.
  • Design and implement critical studies required to drive hypothesis-driven research.
  • Collaborate across multiple projects / roles in a matrixed environment.
  • Present complex concepts to a range of audiences including governance and full team project meetings.
  • Utilize excellent communication and interpersonal skills to drive collaboration and alignment with key stakeholders.
Desired Qualifications
  • Ph.D. or equivalent advanced degree in immunology, immuno-oncology, tumor immunology, or a related field
  • 2+ years of relevant academic and / or industry experience
  • Knowledge of T cell biology and relevant *in vitro* assay systems and experience with transformed tumor cells is strongly preferred.
  • Experience with technologies typically employed to engineer cell lines and assess immune cell function including but not limited to subset of CRISPR, RNAi, Luminex, MSD, IncuCyte-based assays, multi-parameter flow cytometry, T cell activation assays, T cell proliferation assays, imaging technologies.
  • Demonstration of hypothesis-driven, in-depth, innovative thinking and experimentation
  • Self-motivated and focused with project management-oriented thinking; able to work on multiple projects in a matrix environment
  • Ability to communicate well with peers, supervisors, and governance committees.
  • Strong problem-solving skills and understanding of complex scientific principles.
  • Requires strong organizational skills to ensure thorough and timely documentation of experiments, and preparation of data for compiling reports for both internal and external documents.
  • Experience with antibody drug discovery and target identification / validation is an advantage.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. Unlike many competitors, BMS emphasizes sustainability and corporate responsibility, focusing on Environmental, Social, and Governance (ESG) goals. Their goal is to improve patient outcomes by providing both innovative and affordable healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.